Novartis names drugs chief as CEO to deliver return to growth

ZURICH (Reuters) - Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth.